ep beat cf revenu in-line guidanc
unchang investor focus trikafta launch
dynam data aatd data pt
ep beat vs con total product revenu
in-line consensu increas y/i kalydeco vs
con orkambi vs con miss wherea symdeko
beat vs con management left revenu guidanc unchang
updat
takeaway call trikafta management reiter target cf
popul consist patient current
treat exist vertex cf drug elig treatment
management anticip rate limit step trikafta uptak capac
cf center recruit assess dose elig patient management
cf center expect major elig cf patient ultim
treat trikafta us reimburs management expect major
roadblock encourag fact work
payer year payer appreci sever cf clinic benefit
cf drug england reimburs management expect patient
reimburs long-term given penetr rate
complianc rate management plan submit trikafta process
reimburs trikafta receiv market author ema
real-world long-term data collect reimburs cf drug
demonstr clinic benefit cf complet review
potenti amend methodolog evalu long-term clinic benefit
new treatment management expect outcom factor potenti
secur favor reimburs trikafta aatd program
management state phii poc studi initi compris
patient zz mutat main endpoint poc studi includ
safety/toler well level function aatd blood
phii trial expect guid dose select phiii studi management also
comment recent fda workshop regul appreci
investig therapi target lung liver
manifest aatd recogn market aatd therapi
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
approv base aatd augment mention work
sponsor decid design phiii studi base need
approv deep dive aatd see note
program management reiter data phi/ii studi announc
data come patient beta-thalassemia sickl cell
diseas mainli includ safety/toler well hemoglobin
hemoglobin level program fsg management highlight
phi trial healthi subject complet poc studi
commenc poc studi evalu amount protein
urin proteinuria endpoint import fsg constitut
proof biolog also management clarifi target mediat
fsg fsg type type diseas affect major
african-american fsg patient symptom devast
fsg type management offer preliminari expens guidanc
suggest expens grow faster tradit histor
given invest build cell gene therapi
execut remain near-term key pipelin upsid driver management deliv
clean quarter investor focu shift trikafta launch dynam
expect robust given signific efficaci establish
patient popul data updat includ phi/ii readout
gene therapi program hemoglobinopathi await key updat
aatd pain program vertex remain clean growth stori
signific downsid protect clear pipelin upsid option key
stock
triplet approv
triplet approv uptak life-cycl manag oper margin drive
uptak life-cycl manag oper margin drive
ww penetr across cf medicin life-cycl extens extend
franchis bull case assum higher penetr tripl
therapi het/min homozygot patient ww sale
cf aatd us eu commerci success key
mainten key cf franchis life-cycl extens base case
assum penetr tripl combin homozygot
heterozygot risk-adjust peak ww sale cf
modest orkambi uptak tripl combin fail achiev approv
het/min popul bear case assum penetr
triplet total peak ww sale cf aatd therapi peak
overweight vertex believ
initi tripl data replic phiii
studi see vertex clear leader
cf therapi believ manag
potenti deliv ep
initi phi phii data tripl
het/min popul better
kalydeco-lin efficaci
homozyg popul thu includ
risk-adjust tripl combin revenu
base case
efficaci data aatd mice model
suggest efficaci corrector human
therefor model includ risk-
adjust revenu corrector
believ potenti
competit believ vertex
signific advantag posit
on-market doubl combin in-
share competitor long-
main driver vertex phiii
tripl studi time approv launch
uptak therapi
orkambi/kalydeco/tez/iva triplet
risk achiev price
combo penetr fall short
kalydeco sale fail meet
data clinic candid tripl
combin fail meet expect
data competit exce
clinic trial nda file
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
septemb benefici own class common equiti secur follow compani cover
within last month manag co-manag public offer offer secur alector inc
within last month receiv compens invest bank servic alector inc ascendi
next month expect receiv intend seek compens invest bank servic akebia
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani alector inc amgen inc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc beigen ltd biogen inc biomarin
 co llc make market secur alector inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
use rel rate system use term overweight equal-weight not-rat underweight see definit morgan
stanley assign rate buy hold sell stock cover overweight equal-weight not-rat underweight equival
buy hold sell investor care read definit rate use morgan stanley research addit sinc morgan stanley research
contain complet inform concern analyst view investor care read morgan stanley research entireti infer
content rate alon case rate research use reli upon invest advic investor decis buy sell
stock depend individu circumst investor exist hold consider
septemb
stock rate describ appli fundament equiti research appli debt research produc firm
disclosur purpos accord nasd nyse requir includ categori head buy hold sell alongsid
